CurQD + Vedolizumab for Ulcerative Colitis

(Curve UC Trial)

This trial aims to test the effectiveness and safety of a new combination treatment for people with ulcerative colitis (UC), a condition that causes inflammation in the colon. Participants will receive either CurQD, a mix of curcumin and QingDai, or a placebo (inactive pill), along with vedolizumab, a medication already used for UC. The study seeks individuals who have had active UC for more than three months and experience frequent symptoms like rectal bleeding. As a Phase 4 trial, this research helps determine how the already FDA-approved and proven effective treatment benefits more patients.

You can continue taking your current medications if they are stable doses of certain drugs like corticosteroids, methotrexate, azathioprine, 6-mercaptopurine, oral 5-aminosalicylates, mesalamine, sulfasalazine, probiotics, or anti-diarrheal medications. However, you cannot take certain biologic therapies or calcineurin inhibitors before or during the trial.

A previous study found CurQD, a mix of curcumin and QingDai, to be safe. Most patients experienced only minor side effects, indicating that CurQD is generally well-tolerated. Furthermore, the European Crohn's and Colitis Organisation guidelines mention CurQD, adding to its safety credibility.

Unlike other treatments for ulcerative colitis that primarily focus on suppressing inflammation, CurQD combines curcumin and QingDai to potentially offer a novel approach. Curcumin, a natural compound found in turmeric, is known for its anti-inflammatory properties, while QingDai, a traditional Chinese medicine, contributes additional anti-inflammatory effects. Researchers are excited about CurQD because it targets inflammation through these unique natural ingredients, offering a potentially safer and complementary option to existing biologics like vedolizumab. This innovative combination could lead to improved patient outcomes with fewer side effects.

Studies have shown that CurQD, a mix of curcumin and QingDai, effectively treats ulcerative colitis (UC). Clinical trials have demonstrated that this combination helps patients achieve remission, significantly improving or eliminating symptoms. In this trial, participants will receive either CurQD or a placebo. CurQD activates a part of the immune system that reduces gut inflammation, a major issue in UC. Overall, CurQD has shown promising results in managing UC symptoms.⁴⁵⁶⁷⁸